Trikafta was associated with significant reductions in healthcare use, including hospitalizations related to cystic fibrosis (CF) complications affecting organs and systems outside the lungs, according to an insurance claims analysis. “Results of this study suggest a multisystemic benefit of [Trikafta] therapy with reductions in extrapulmonary…